Background: Neoplasms of the oral maxillofacial area are an interesting entity characterized by differences in nomenclature and classification at different centers. Neoplasms of the oral maxillofacial area are a source of great differences in nomenclature and classification making comparison from different countries difficult. Reports from different parts of the world show differences in the pattern of maxillofacial tumors seen. [1-5] A couple of authors have revisited the histopathological slides of certain groups of maxillofacial tumors in their centers with the aim of reclassifying the diagnoses made at the time to bring them in line with the current WHO classification.

We report neoplastic histopathological diagnoses seen at the departments of oral maxillofacial surgery of Muhimbili and Mulago referral hospitals in Tanzania and Uganda respectively over a 10-year period.

Methods: We retrieved histopathological reports archived at the departments of oral maxillofacial surgery of Muhimbili and Mulago referral hospitals in Tanzania and Uganda respectively over a 10-year period from June 1989–July 1999.

Results: In the period between June 1989 and July 1999, 565 and 1298 neoplastic oro-facial cases were retrieved of which 284 (50.53%) and 967 (74.54%) were malignant neoplasms at Muhimbili and Mulago hospitals respectively. Overall 67.28% of the diagnoses recorded were malignant with Kaposi’s sarcoma (21.98%), Burkitt’s lymphoma (20.45%), and squamous cell carcinoma (15.22%) dominating that group while ameloblastoma (9.23%), fibromas (7.3%) and pleomorphic adenoma (4.95%) dominated the benign group.

The high frequency of malignancies could be due to inclusion criteria and the clinical practice of selective histopathology investigation. However, it may also be due to higher chances of referrals in case of malignancies.

Conclusion: There is need to reexamine the slides in these two centers in order to bring them in line with the most recent WHO classification so as to allow for comparison with reports from elsewhere.
This is meant to bring sanity in the body of research and clinical records. Uganda at the moment has only one serving oral pathologist and Tanzania is no better, hence reliance on already over-stretched general pathologists to do the oral histopathological diagnosis. The burden of tropical infectious diseases such as malaria, tuberculosis and HIV/AIDS relegates oro-facial diseases to the bottom of the priority list by both government and donor agencies. Although some work has been reported on these neoplasms from East Africa, most was done years back and the numbers reported were few.

In 1956, Pritam and Cook reported sarcomas, adamantinoma and carcinomas as the commonest oral maxillofacial neoplasms in Uganda. [8] Four years later Dodge reported an unusually high incidence of odontogenic tumors in Ugandan Africans. [9] However, when Slavin and Cameron reported on ameloblastoma from both Uganda and Tanzania they attributed the high numbers to a harvesting period. [10] Recently Simon et al reported that some of the tumors that were initially thought to have a racial preponderance for African blacks are in fact equal in incidence with other parts of the world. [11] Although Wakiaga J.M et al in a report from Kenya had high number of cases, they restricted inclusion to cases of jaw tumors only. Ameloblastoma, Burkitts lymphoma, ossifying fibroma and osteogenic sarcoma were reported as being the commonest in that order. [12]

We felt that an update on the different histopathological entities reported and recorded at the oral maxillofacial surgery departments in East Africa was long overdue. We hope it will show the huge discrepancies in classification with the standing WHO classification and as a result generate interest and funding so as to streamline our records.

Methods
Mulago Hospital and Muhimbili National Referral Hospitals are the two biggest referral hospitals for Uganda and Tanzania respectively. They were the main treatment centers for oral maxillofacial neoplasms until recently when some other oral referral centers in Tanzania got the personnel to man the departments. They both house the national cancer registry at the departments of human pathology and morbid anatomy. The normal procedure is that the histopathological results are filed at both the relevant departments as well as the department of human pathology and morbid anatomy.

The data presented here was obtained from the biopsy results files in the departments of oral maxillofacial surgery and oral pathology at both hospitals stretching from June 1989 to July 1999. The choice of the time interval was due to the fact that from the year 2000 some regional referral hospitals in Tanzania had set up oral and maxillofacial surgery departments hence reducing the catchment area for Muhimbili hospital. The tumor type, age, sex and site of lesions were recorded in a pre-designed data collection form. During data collection, the diagnoses were recorded as reported on the biopsy result slips. However, “unspecified” such as undetermined malignancies and those that gave histological characteristics but no final diagnoses were excluded from the study during analysis. Reports of fine needle aspiration cytology and microscopy of blood or fluid smears were excluded. Repeat biopsies were counted once with the later diagnosis taken. This was in light of the fact that at both centers the previous biopsy number is recorded when a repeat is done allowing the pathologists to review the old slide alongside the repeat slide enabling a more informed decision. Those repeat biopsies that were done due to recurrence after treatment were recorded once except if the second time around a different diagnosis was given. Non neoplastic cysts, dysplastic and inflammatory lesions were excluded from the study.

An interval of 10 years was used to classify the data into age groups. As for those that were not specified or recorded as adult, they were categorized as unknown while the ones recorded as child were placed under the 10 years and below.

The site of the neoplasm was taken as recorded on the slips. However, those cases appearing adjacent to major salivary glands should be taken with caution. The lip included both lower and upper while the palate represented hard and soft palate. Site recorded as oral cavity was restricted to the common sites, floor of the mouth, gingival and buccal mucosa.

Statistical analysis including student’s t tests and simple proportion tests done using excel Microsoft office 2003.

Results
In the period between June 1989 and July 1999, 565 and 1298 neoplastic oro-facial cases were retrieved of which 284 (50.53%) and 967 (74.54%) were malignant neoplasms at Muhimbili and Mulago hospitals respectively. In Tanzania (Muhimbili hospital), squamous cell carcinoma (32.75%) was the commonest in the malignant category followed by Burkitts lymphoma (32.40%) and Kaposis sarcoma (15.14%). Only one case of malignant odontogenic neoplasm (malignant ameloblastoma) was reported.

On the other hand, in Uganda (Mulago hospital), Kaposis sarcoma (37.78%) was the commonest malignant neoplasm followed by Burkitts lymphoma (30.12%)then
squamous cell carcinoma (19.67%). Combined data (i.e. Muhimbili plus Mulago), malignant neoplasms were 67.28% of all retrieved results with Kaposia sarcoma (32.64%), Burkitt's lymphoma (30.56%) and squamous cell carcinoma (22.64%) dominating.

As for the benign neoplasms, ameloblastoma (35.61%), pleomorphic adenoma (17.63%) and fibromas (17.57%) were the most frequent in Tanzania while in Uganda it was fibromas (26.67%), ameloblastoma (22.12%), pleomorphic adenoma (13.03%) and papilloma (10.6%). The different diagnoses seen at the two hospitals are shown in Table 1. Overall, odontogenic neoplasms were 11.73%, 9.8% (Uganda) 15.30% (Tanzania).

The gender distribution of the different neoplasms is as shown in Table 2. Of the retrieved cases 53.71% were males compared to 45.32% females and 0.97% were not specified. The over all the male female ratio was 1.2:1, 1.3:1 in Tanzania compared to 1.14:1 in Uganda. Of the male cases 71.74% were malignant compared to 61.88% among females.11.12% of the male neoplasms were odontogenic compared to 21.65% of the female cases.

Age distribution of the different diagnosis is shown in table 3. The overall average age was 29.29 ± 19.72 with a range of 0.06–97 years. The neoplasms showed a wide range of age distribution with most neoplasms peaking in the second and third decade except Burkitts lymphoma that peaked below 10 years (Figure 1). Squamous cell carcinoma peaked in the sixth decade and dominated malignancies in the sixth decade upwards.

The site distribution of some selected neoplasms is as summarized in table 4. The neoplasms had different site predilections. For instance 55.72% of neoplasms whose site was recorded as the mandible were ameloblastoma while 56.4% of the palatal cases were Kaposia sarcoma. Unfortunately, in over 50% of all the slips, the site of biopsy wasn't recorded.

**Discussion**

In this study, malignant maxillofacial neoplasms accounted for up to 67.28% a figure that is very high compared to other reports. [1,3,5] However, the other reports included cysts, granulomas and inflammatory conditions and thus malignancies expressed as a percentage of all the biopsies were bound to be lower. A high frequency of malignancies has been reported by some African studies such as Chidzonga et al and Aregbesola et al compared to Asian, American or European reports. [2-5,13] This could be due to differences in clinical practice whereby in some centers all surgical specimens are sent out for histological investigations, while in others radiographic and clinical features are used as criteria for what needs histopathological investigation. In our study, the exclusion of non neoplastic cysts, hyperplastic and inflammatory lesions combined with the clinical practice of selective histological investigations and high likelihood of referral in case of malignancy, may explain the high frequency of malignancies reported. We decided to leave out the inflammatory and hyperplastic lesions since in many instances they are recorded as no cancer seen which made it difficult to include them in the study. Final diagnosis such as no cancer seen may be due to reliance on already over-stretched general pathologists to diagnose oral pathological slides. Tay et al encountered a similar problem when it came to oral histology reports from general pathologists. [3] The commonest malignancy in these series was Kaposia sarcoma (21.98%) a neoplasm not reported by Tay et al, Krutchkoff et al, Ogunbodede et al. [3,13,14] Jones et al reported KS lesion (0.3%) at a UK center but the percentage was low compared to our study. [5] This may be due to the fact that KS biopsies are obtained from the skin in other centers. On the other hand Mbulaiteye SM et al reported an increased standardized incidence risk for KS among HIV infected persons of 6.4 (95% CI 4.8–8.4) and therefore many of these biopsies are likely to have been from HIV infected individuals. Additionally Goedert et al earlier on reported a 310 fold increase in risk of acquiring KS following HIV infection while Ziegler et al reported a 40 fold increment with the oro-facial dominant pattern accounting for up to 79% of the cases in Uganda. [15-17] In this study Uganda contributed the bulk of Kaposia sarcoma cases as shown in table 1, hence Ziegler et al's report may be a good explanation for this unusually high frequency of KS in our series. However, it is worth noting that this is highly speculative since we don't have the HIV status of the cases diagnosed with Kaposia's sarcoma. Presently the picture may be different given the increased availability of highly active antiretroviral therapy (HART), which have been reported to decrease the prevalence of some AIDS-associated oral facial conditions. [18,19] A recent study in Tanzania noted a very low prevalence of Kaposia sarcoma among patients on HART. [20] It would be interesting to do research on the trend of Kaposia's sarcoma with the advent of HART versus the period prior. There was equal sex distribution of KS (Table 2), suggesting that the exposure to risk factors is equal. The majority of the KS cases (69.68%) were in the 3rd and 4th decade (Table 3). This tallies with the HIV AIDS prevalence that is highest in the 3rd and 4th decades. [21,22] The palate and tongue were the commonest sites for KS lesions (47.55%, 32.64%), Burkitt's lymphoma (20.54%). However, in Tanzania, Burkitt's
Table 1: Distribution of oralfacial neoplasms in Mulago Uganda (UG) and Muhimbili Tanzania (TZ)

| Diagnosis                                      | Abbreviation | UG | TZ | % of overall |
|------------------------------------------------|--------------|----|----|--------------|
| Ameloblastoma                                   | AME          | 73 | 99 | 9.23         |
| Odontogenic myxoma                              | MYX          | 6  | 15 | 1.13         |
| Ameloblastic fibroma                            | AMEF         | 1  | 3  | 0.21         |
| Adenomatoid odontogenic tumour                  | AOT          | 1  | 1  | 0.11         |
| Odontoma                                        | ODT          | 1  | 0  | 0.05         |
| Odontogenic fibroma                             | ODF          | 0  | 5  | 0.27         |
| Malignant ameloblastoma                         | MAME         | 0  | 1  | 0.05         |
| Fibroma                                         | FIB          | 88 | 48 | 7.30         |
| Ossifying fibroma                               | OF           | 0  | 2  | 0.11         |
| Cementifying fibroma                            | CF           | 4  | 5  | 0.48         |
| Chondroma                                       | CHD          | 1  | 2  | 0.16         |
| Osteoma                                         | OST          | 5  | 4  | 0.48         |
| Osteosarcoma                                    | OSS          | 2  | 5  | 0.38         |
| Fibrosarcoma                                    | FIS          | 4  | 1  | 0.27         |
| Chondrosarcoma/Chondro myxoid fibro sarcoma     | CHS          | 7  | 1  | 0.43         |
| Myxoid sarcoma                                  | MYXS         | 1  | 0  | 0.05         |
| Round cell carcinoma                            | RCS          | 0  | 1  | 0.05         |
| Burkitts lymphoma                               | BUR          | 291| 91 | 20.54        |
| Non Hodgkin’s lymphoma                          | NHL          | 11 | 6  | 0.91         |
| Histiocytic lymphoma                            | HLH          | 1  | 0  | 0.05         |
| Centroblastic polymorphic lymphoma              | CPL          | 0  | 1  | 0.05         |
| Squamous cell carcinoma                         | SCCa         | 190| 93 | 15.22        |
| Anaplastic carcinoma                            | ACa          | 9  | 8  | 0.86         |
| Uni/Poorly differentiated carcinoma              | UCa          | 19 | 0  | 1.02         |
| Nasopharyngeal carcinoma                        | NPCa         | 1  | 0  | 0.05         |
| Non keratinizing carcinoma of tonsil            | NKTca        | 0  | 1  | 0.05         |
| Verrucous carcinoma                             | Vca          | 3  | 3  | 0.32         |
| Bassal cell carcinoma                           | BCCa         | 0  | 1  | 0.05         |
| Adenoma                                         | ADN          | 16 | 3  | 1.02         |
| Pleomorphic adenoma                             | PLA          | 43 | 49 | 4.95         |
| Monomorphic adenoma                             | MOA          | 0  | 1  | 0.05         |
| Oxyphill cell adenoma                           | OCA          | 3  | 0  | 0.16         |
| Adeno carcinoma                                 | ADCa         | 22 | 10 | 1.72         |
| Adenocystic carcinoma (Cylindroma)              | ACCa         | 14 | 5  | 1.02         |
| Salivary gland carcinoma                        | SGCa         | 2  | 1  | 0.16         |
| Mucous secreting carcinoma                      | MSCa         | 4  | 0  | 0.22         |
| Muco epidermoid carcinoma                       | MECa         | 5  | 4  | 0.48         |
| Carcinoma ex pleomorphic adenoma                | CaPLa        | 1  | 0  | 0.05         |
| Haemagio pericytoma                             | HAP          | 2  | 2  | 0.22         |
| Kaposis sarcoma                                 | KS           | 365| 44 | 21.98        |
| Haemagio sarcoma                                | HAS          | 0  | 1  | 0.05         |
| Granular cell myoblastoma                       | GCM          | 6  | 0  | 0.32         |
| Leiomyoma                                       | LEI          | 0  | 1  | 0.05         |
| Rhabdomyosarcoma                                | RHS          | 8  | 1  | 0.48         |
| Lymphagioma                                     | LPH          | 11 | 1  | 0.65         |
| Lymphangiosarcoma                               | LPHS         | 0  | 1  | 0.05         |
| Lipoma                                          | LIP          | 19 | 10 | 1.56         |
| Liposarcoma                                     | LIS          | 1  | 1  | 0.11         |
| Melanotic progonoma                             | MEP          | 1  | 0  | 0.05         |
| Melanoma                                        | MEL          | 5  | 2  | 0.38         |
lymphoma came in third after squamous cell carcinoma (Table 1). Burkitt's lymphoma has been consistently reported at high frequencies in African series but not Asian and American series. [3,4,12,23,24] This has led to speculations as to why such a high frequency occurs in Africa. The various reasons advanced include geographical, HIV/AIDS, socio economic factors, nutrition, viral infections and genetic. [14,16,25,26] In our study it's hard to explain the high frequency hence more studies are required to investigate whether the improving situation in African countries is showing reduction in this tumor to levels close to those seen in other parts of the world. A recent study from Kenya reported geographical differences in clinical features of Burkitt's lymphoma. The coastal, western and central regions had facial swelling as the presenting complaint in 81%, 64% and 31% respectively. [27] Such a phenomenon could lead to a high number of Burkitt lymphomas in oral facial biopsies in some centers compared to others and may as well explain the huge numbers in Uganda compared to Tanzania and absence of Burkitt's lymphoma in some studies from Africa. The gender distribution was similar to other reports from Nigeria and Kenya with boys being more affected than girls (table 2). [4,12,27] The mean age at diagnosis was $7.21 \pm 0.513$ years with a range of 2–45 (table 3). It is worth noting that in this study 89.3% were under the age of 10 and 9.2% between 10 and 20 years. The frequency distribution of those below 10 is as shown in figure 1. These findings agree with other reports from other parts of Africa. [4,12,24] The site of Burkitt's lymphoma was recorded in only 77 cases (mandible 65%, the jaws i.e. both maxilla and mandible accounted 9.1% and maxilla 14.9%). Although very few cases had the site recorded, the results are in agreement with already published reports. [4,12] There were 17 cases reported as non Hodgkin's lymphoma of which only two were below 10 years and 8 over 40 years. These could have been any other types of non hodgkins lymphoma such as large cell lymphoma. Jones et al [5] had non Hodgkin's lymphoma ranked as second commonest malignancy in their study.

The third commonest malignancy was squamous cell carcinoma accounting for 15.22% overall. This was different when compared to reports from other African studies and the rest of the world that report squamous cell carcinoma as the most frequent malignancy. [1-3,14] However, it should be noted that the differences in inclusion criteria, clinical practices make it impossible to objectively compare these findings with others. For instance neither the Asian and American studies report of any case of Burkitt's lymphoma nor does the Jordanian study despite the fact that it was based on children and adolescents. [1,3,23]. The difference between our study and those from Zimbabwe [2] and Nigeria [14] could be due to the high number of KS cases that were not included in those two studies. When we considered only the tumors in the Nigerian study, squamous cell carcinoma prevalence in Tanzania increased to nearly equal levels as those reported in Nigeria but in Uganda the high number of Burkitt's lymphoma cases still pulled down the prevalence of squamous cell carcinoma. This has been reported in a different Nigerian study hence giving some credence to our argument. [28] The gender and age distribution are shown in tables 2 and 3. The Mean age didn't differ from that of the individual countries. The modal age group in both hospitals was 51–60 ($p \geq 0.01$). This is in line with what was expected since squamous cell carcinoma is known to mainly affect older individuals. However, interestingly in Tanzania males were more affected which is in line with most parts of the world but in Uganda there was equal sex distribution. Some studies from other parts of the world have already noted an increase in oral cancer incidence among females but stable rates among men. [28-31] This is attributed to equal exposure to cancer risk factors between women and men and probably over time Tanzania will register a similar trend as Uganda in terms of equal prevalence among women and men. Unfortunately the Kenyan study didn't report on squamous cell carcinoma to allow comparison. [12] The tongue, floor of the mouth and buccal surface were the commonest sites among those specified. The tongue as a site of head and neck cancer ranked high in Nigeria and the incidence of lingual squamous cell carcinoma has been reported to be on the increase in America. [28,32] It's worth noting that unlike the Nigerian study from Ile Ife where no cancer of the buccal mucosa was reported, it was the third commonest malignancy accounting for 15.22% overall. This was different

| Table 1: Distribution of oralfacial neoplasms in Mulago Uganda (UG) and Muhimbili Tanzania (TZ) (Continued) |
|---------------------------------|---|---|---|
| Hamartoma | HAM | 4 | 2 | 0.32 |
| Papilloma | PAP | 35 | 22 | 3.06 |
| Neurofibroma | NEF | 10 | 2 | 0.65 |
| Schwannoma | SCH | 0 | 2 | 0.11 |
| Mesenchymoma | MSA | 0 | 1 | 0.05 |
| Calciifying Epithelioma of Malherbe | CEM | 1 | 1 | 0.11 |
| Chodro Syrigoma | CHSY | 1 | 0 | 0.05 |
| Retinoblastoma | REBA | 0 | 1 | 0.05 |
| TOTAL | 1298 | 565 |
Table 2: Gender distribution of the oral facial neoplasms

| Abbreviation | Females | Males | Unspecified | Total | M:F Ratio |
|--------------|---------|-------|-------------|-------|-----------|
|              |         |       |             |       | UG/TZ     |
| AME          | 73      | 97    | 2           | 172   | 1.28:1    | 1.36:1    |
| MYX          | 15      | 4     | 2           | 21    | g         | 1.25:1    |
| AMEF         | 4       | -     | -           | -     | g         | g         |
| AOT          | 1       | 1     | -           | 2     | g         | g         |
| ODT          | 1       | -     | -           | 1     | g         | g         |
| ODF          | 3       | 2     | -           | 5     | 1:1:1.5   |           |
| MAME         | 1       | -     | -           | 1     | g         | g         |
| FIB          | 79      | 57    | -           | 136   | 1:1:3:12  | 1:1:53    |
| OF           | 2       | -     | -           | 2     | g         | g         |
| CF           | 6       | 3     | -           | 9     | g         | g         |
| CHD          | 1       | 2     | -           | 3     | g         | g         |
| OST          | 1       | 8     | -           | 9     | 3:1:3     |           |
| OSS          | 2       | 5     | -           | 7     | 1:1:4     |           |
| FIS          | 4       | 1     | -           | 5     | g         | g         |
| CHS          | 2       | 6     | -           | 8     | 1:1:6     |           |
| MYXS         | -       | 1     | -           | 1     | g         | g         |
| RCS          | -       | -     | -           | 1     | g         | g         |
| BUR          | 252     | 128   | 2           | 382   | 1:8:1:93  | 2:2:5:1   |
| NHL          | 5       | 12    | -           | 17    | 1:1:75:1  | 1:1       |
| HLH          | 1       | -     | -           | 1     | g         | g         |
| CPL          | -       | 1     | -           | 1     | g         | g         |
| SCCa         | 126     | 153   | 4           | 283   | 1:1:1:1   | 1:9:1     |
| ACa          | 9       | 8     | -           | 17    | 1:1:2:5   | 1:1       |
| UCa          | 6       | 13    | -           | 19    | 2:2:1:1   |           |
| NPCa         | 1       | -     | -           | 1     | g         | g         |
| NKTCa        | -       | 1     | -           | 1     | -         | g         |
| Vca          | 1       | 5     | -           | 6     | g         | 2:1       |
| BCCa         | 1       | -     | -           | 1     | g         | g         |
| ADN          | 10      | 8     | 1           | 19    | 1:1:1     |           |
| PLA          | 51      | 41    | -           | 92    | 1:1:1:3   | 1:1:1:2   |
| MOA          | 1       | -     | -           | 1     | -         | g         |
| OCA          | 3       | -     | -           | 3     | g         | g         |
| ADCa         | 15      | 17    | -           | 32    | 1:1:1:2   | 1:1       |
| ACCa         | 10      | 7     | 2           | 19    | 1:1:1:6   | 1:1       |
| SGCa         | 1       | 2     | -           | 3     | 1:1:1     | 2:1       |
| MSCa         | 1       | 3     | -           | 4     | 3:1:1     |           |
| MEca         | 2       | 7     | -           | 9     | 1:1:5:1   |           |
| CaPLA        | -       | -     | -           | 1     | g         | g         |
| HAP          | 1       | 3     | -           | 4     | 2:1:1     |           |
| KS           | 199     | 208   | 2           | 409   | 1:1:1:1   | 1:1       |
| HAS          | 1       | -     | -           | 1     | g         | g         |
| GCM          | 5       | 1     | -           | 6     | 1:2:5:1   |           |
| LEI          | 1       | -     | -           | 1     | -         | g         |
| RHS          | 2       | 7     | -           | 9     | 1:1:3:1   |           |
| LPH          | 7       | 5     | -           | 12    | 1:1:75:1  |           |
| LPHS         | -       | 1     | -           | 1     | g         | g         |
| LIP          | 13      | 15    | 1           | 29    | 1:1:1:57  | 4:1       |
| LIS          | 1       | 1     | -           | 2     | g         | g         |
est site in our study. [14] On the other hand a study from Zimbabwe had similar trends in anatomical sites with ours. [33] Therefore more research is needed to see if there are differences in anatomical sites affected by squamous cell carcinoma across Africa compared to the rest of the world. Anaplastic carcinoma and undifferentiated/poorly differentiated carcinoma accounted for 1.88% of all malignant neoplasms seen. This is similar to what has been reported by Jones et al. [5]

There was only one case of malignant odontogenic neoplasm in these series, which showed the rarity of these entities.

Salivary gland neoplasia is one of the challenging tumors when it comes to histological typing. The WHO classification is aimed at making it easier for researchers to compare prevalence, however, not all centers have re-diagnosed the entity in accordance with it. In this study salivary gland neoplasia accounted for about 9% of both malignant and benign neoplasms, a figure close to that reported from Europe. [5] Pleomorphic adenoma dominated this group. The peak frequency was the 3rd decade with equal gender distribution, however, reports from Brazil and Italy showed a female preponderance. [5,34-36] Multi center studies are needed to see if there is real sex predilection or not. Adenoma was the second commonest benign neoplasm. A figure close to that reported from Europe. [5] Pleomorphic adenoma dominated this group. The peak frequency was the 3rd decade with equal gender distribution, however, reports from Brazil and Italy showed a female preponderance. [5,34-36] Multi center studies are needed to see if there is real sex predilection or not. Adenoma was the second commonest benign neoplasm. The peak frequency was the 3rd decade with equal gender distribution, however, reports from Brazil and Italy showed a female preponderance. [5,34-36]

Table 2: Gender distribution of the oral facial neoplasms (Continued)

| MEL  | MEP  | HAM | PAP | NEF | SCH | MSA | CEM | CHSY | REBA | TOTAL |
|------|------|-----|-----|-----|-----|-----|-----|------|------|-------|
| 4    | 1    | 3   | 4   | 6   | 2   | -   | 1   | -    | -    | 974   |
| 3    | -    | -   | 20  | 6   | -   | 2   | -   | 1    | 1    | 871   |
| 2    | 31   | 6   | 11  | 12  | 2    | 11  | 1   | 1    | 1    | 18    |
| -    | 34   | -   | -   | 1   | 1    | 1   | -   | -    | -    | 1863  |

Among the benign non odontogenic neoplasms including salivary gland neoplasms, fibromas, pleomorphic adenoma and papillomas were the commonest in descending order. This differs from the report by Jones et al [5] in which papillomas then pleomorphic adenomas were ranked as first and second. This is hard to draw conclusions. Both fibromas and papillomas had a slight predilection for females which is in contrast with Jones et al. It should be noted that the numbers in our study are small compared to Jones et al hence this could be a chance finding. The site distribution of these neoplasms was varied as can be seen in table 4. Unfortunately, in the majority of the lesions, the sites were not specified.

Lipomas were also relatively frequent with the demographics all being in line with published reports. In our
## Table 3: Combined age distribution of oral facial neoplasms biopsy results

| Dx  | 0–10 | 11–20 | 21–30 | 31–40 | 41–50 | 51–60 | 61–70 | 71–80 | 81–90 | 91+ | US | mean | Range |
|-----|------|-------|-------|-------|-------|-------|-------|-------|-------|-----|-----|-------|-------|
| AME | 2    | 36    | 54    | 33    | 14    | 11    | 3     | 1     | -     | -   | 18  | 30.52 | 5–75  |
| MYX | 5    | 4     | 5     | 1     | 1     | 1     | -     | -     | -     | -   | 3   | 22.42 | 6–64  |
| AMEF| 1    | 1     | 1     | -     | -     | -     | -     | -     | -     | -   | 1   | 27.67 | 15–38 |
| OAT | -    | 1     | -     | -     | -     | -     | -     | -     | -     | -   | 1   | *    | *     |
| ODT | -    | -     | 1     | -     | -     | -     | -     | -     | -     | -   | *   | *    | *     |
| ODF | -    | 3     | 2     | -     | -     | -     | -     | -     | -     | -   | 19.80 | 14–25 |
| MAME| -    | -     | -     | 1     | -     | -     | -     | -     | -     | -   | *   | *    | *     |
| FIB | 18   | 30    | 22    | 22    | 11    | 11    | -     | -     | -     | -   | 3   | 31.00 | 0.5–70 |
| OF  | -    | -     | -     | -     | -     | -     | -     | -     | -     | -   | 2   | *    | *     |
| CF  | -    | 3     | 4     | -     | -     | -     | -     | -     | -     | -   | 1   | 27.00 | 12–52 |
| CHD | -    | -     | 1     | 1     | -     | -     | -     | -     | -     | -   | 40.50| 30–58 |
| OST | 2    | 2     | 4     | -     | -     | -     | -     | -     | -     | -   | 21.60| 8–41  |
| OSS | -    | 1     | 1     | 1     | 3     | -     | -     | -     | -     | -   | 1   | 35.20 | 20–45 |
| FIS | 1    | 1     | 1     | -     | 2     | -     | -     | -     | -     | -   | 1   | 26.00 | 6–40  |
| CHS | -    | 1     | 2     | 3     | 1     | -     | -     | -     | -     | -   | 1   | 30.71 | 14–49 |
| MYXS| -    | -     | -     | 1     | -     | -     | -     | -     | -     | -   | *   | *    | *     |
| RCS | -    | 1     | -     | -     | -     | -     | -     | -     | -     | -   | *   | *    | *     |
| BUR | 341  | 35    | 2     | -     | 1     | -     | -     | -     | -     | -   | 3   | 7.21  | 2–45  |
| NHL | 2    | 5     | 1     | 1     | 2     | 2     | 4     | -     | -     | -   | 35.33| 1.5–63 |
| HLH | -    | -     | -     | 1     | -     | -     | -     | -     | -     | -   | *   | *    | *     |
| CPL | -    | -     | -     | -     | -     | -     | -     | -     | -     | -   | *   | *    | *     |
| SCCa| 1    | 2     | 18    | 28    | 56    | 78    | 51    | 20    | 4     | 2   | 23  | 31.78 | 1.6–68 |
| ACCa| 2    | 1     | 3     | 1     | 2     | 2     | 3     | -     | 2     | -   | 3   | 54.50 | 18–60 |
| UCa | -    | -     | 2     | 4     | 5     | 3     | 2     | 2     | -     | -   | 1   | 49.22 | 23–72 |
| NPCa| -    | -     | 1     | -     | -     | -     | -     | -     | -     | -   | *   | *    | *     |
| NKTCa| -    | -     | -     | 1     | -     | -     | -     | -     | -     | -   | *   | *    | *     |
| Vca | -    | -     | 1     | 1     | -     | 3     | -     | -     | 1     | -   | 53.84| 22–80 |
| BCCa| -    | -     | -     | -     | 1     | -     | -     | -     | -     | -   | *   | *    | *     |
| ADN | 2    | 3     | 7     | 2     | 2     | 2     | 1     | 1     | -     | -   | 1   | 29.16 | 3.1–61 |
| PLA | 3    | 14    | 30    | 19    | 9     | 6     | 6     | 1     | -     | -   | 4   | 32.58 | 5–71  |
| MOA | -    | -     | -     | 1     | -     | -     | -     | -     | -     | -   | *   | *    | *     |
| OCA | -    | 3     | -     | -     | -     | -     | -     | -     | -     | -   | 19.00| 17–20 |
| ADCa| -    | 2     | 6     | 6     | 4     | 9     | 2     | 3     | -     | -   | 46.78| 18–80 |
| ACCa | 3    | 2     | 1     | 6     | 4     | 1     | 1     | -     | -     | -   | 46.86| 20–65 |
| SGCa| -    | -     | -     | 1     | 2     | -     | -     | -     | -     | -   | 52.50| 47–60 |
| MSCa| -    | 1     | -     | 2     | 1     | -     | -     | -     | -     | -   | 33.00| 14–48 |
| MECa| -    | 2     | 1     | 1     | 2     | 2     | -     | -     | -     | -   | 37.22| 13–60 |
| CaPLA| -    | -     | -     | -     | -     | -     | -     | -     | -     | -   | *   | *    | *     |
| HAP | 1    | 2     | -     | -     | -     | -     | -     | -     | -     | -   | 28.50| 7–80  |
| KS  | 30   | 32    | 176   | 109   | 34    | 11    | 4     | -     | -     | -   | 13  | 31.78 | 1.6–68 |
| HAS | -    | -     | -     | -     | -     | -     | -     | -     | -     | -   | 1   | *    | *     |
| GCM | 4    | -     | 1     | -     | 1     | -     | -     | -     | -     | -   | 12.93| 0.6–49 |
| LEI | -    | 1     | -     | -     | -     | -     | -     | -     | -     | -   | *   | *    | *     |
| RHS | 3    | 4     | 1     | -     | 1     | -     | -     | -     | -     | -   | 17.61| 0.7–70 |
| LPH | 6    | 2     | 1     | -     | 2     | -     | -     | -     | -     | -   | 17.61| 0.7–70 |
| LPHS| -    | -     | 1     | -     | -     | -     | -     | -     | -     | -   | *   | *    | *     |
| LIP | 3    | 7     | 6     | 2     | 2     | 3     | -     | 2     | -     | 4   | 33.30| 1–88  |
| LIS | -    | -     | 1     | -     | 1     | -     | -     | -     | -     | -   | 51.50| 36–67 |
| MEP | 1    | -     | -     | -     | -     | -     | -     | -     | -     | -   | *   | *    | *     |
study hamartomas were not classified as odontogenic or non odontogenic yet they are known to occur under both categories. (40) We included them in the non odontogenic neoplasms.

**Conclusion**

The range of diagnosed neoplasms from our study was diverse and our results should be of interest to pathologists, oral and maxillofacial surgeons, specialist practitioners and general dental practitioners. The results do not represent the actual prevalence of oral and maxillofacial disease within the general population, but simply reflect the frequency of histologically diagnosed neoplasms at Mulago and Muhimbili national referral hospitals of Uganda and Tanzania respectively. This survey has shown that most diagnoses are malignant in nature and often require surgical management. However, a large proportion of cases such as odontomas, etc., which are not as aggressive, could have been under represented because of their clinical course and the clinical practices at these centers. The disparities noted between the WHO classification and our report should hopefully generate interest to reclassify oro-facial neoplasms across the world to enable better comparison.

**Competing interests**

The authors declare that they have no competing interests.

**Authors' contributions**

KA Conceived, collected the data and co-wrote the article
KB Co-wrote the article

![Combined age distribution of oral facial neoplasms biopsy results](image)

% frequency distribution expressed out of total Burkitt's cases

**Figure 1**

% distribution of Burkitt's lymphoma for those 10 years and below.
Table 4: Site distribution of some selected oral facial neoplasms in Uganda and Tanzania

| AME | MYX | FIB | BUR | SCCa | PDCa | PLA | ADN | ACCa | KS | PAP |
|-----|-----|-----|-----|------|------|-----|-----|------|----|-----|
| Maxilla | 1 | 6 | 26 | 50 | - | - | - | - | 1 | 1 |
| Mandible | 74 | 1 | 22 | 20 | 4 | 1 | 1 | 1 | - | - |
| Jaws | 6 | - | 2 | 7 | 1 | - | - | - | - | - |
| Tongue | - | - | - | 39 | 1 | - | 1 | 54 | 13 | - |
| Palate | - | - | 3 | 6 | 26 | 2 | 3 | 97 | 3 | - |
| Buccal | - | - | 5 | - | - | - | - | - | - | - |
| Gingiva | - | - | - | - | 3 | - | - | - | - | - |
| Labial | - | - | 2 | - | 7 | 2 | 3 | 2 | 2 | 13 |
| Commisure | - | - | 3 | - | - | - | - | - | - | - |
| Retro molar | - | - | 1 | - | 3 | 1 | - | - | - | - |
| Tuberosity | - | - | - | - | - | - | 1 | 3 | - | - |
| Parotid | - | - | - | - | - | 1 | - | - | - | - |
| Submandibular | - | - | - | - | - | 1 | - | - | - | - |
| Sublingual | - | - | - | - | - | - | 1 | 1 | 1 | 1 |
| Oral cavity | - | - | - | - | - | - | - | - | - | - |
| Mouth floor | - | - | - | - | 21 | 2 | 1 | 1 | - | - |
| Face | - | - | 1 | - | 4 | - | - | - | - | - |
| Neck | - | - | - | - | - | - | 1 | - | - | - |
| Maxillary antrum | - | - | - | - | - | - | - | - | - | - |
| Nasion area | - | - | 4 | - | - | - | - | - | - | - |
| Unspecified | 91 | 14 | 65 | 305 | 171 | 8 | 44 | 9 | 9 | 199 |
| Total | 172 | 21 | 138 | 382 | 283 | 19 | 92 | 19 | 19 | 409 |

Acknowledgements

We would like to express our appreciation to all staff at the histopathology and morbid anatomy departments for the continued diagnosis and filing of all specimens sent to them. Funding was provided by Muhimbili University College of Health Sciences.

We appreciate Dr Tony Giles of mercy ship for correcting the grammar and English of the paper plus his professional opinions.

References

1. Bhaskar SN: Oral pathology in the dental office: Survey of 20,575 biopsy specimens. J Am Dent Assoc 1968, 67:761-6.
2. Chidzonga MM, Lopez VM, Portilla Alvarez AL: Orofacial biopsies: a survey of 1732 cases seen over a 10 year period. Cent Afr J Med 1996, 42:102-8.
3. Tay ABG: A 5 year survey of oral biopsies in an oral surgical unit in Singapore: 1993–1997. Ann Acad Med Singapore 1999, 28:665-71.
4. Aregbesola SB, Ugboke VI, Akinwande JA, Arole GF, Fagade OO: Orofacial tumours in suburban Nigerian children and adolescents. Br J Oral Maxillofac Surg 2005, 43(2):226-231.
5. Jones AV, Franklin CD: An analysis of oral and maxillofacial pathology found in adults over a 30-year period. J Oral Pathol Med 2006, 35:392-401.
6. Mosqueda-Taylor A, Ledesma-Montes C, Caballero-Sandoval S, Portilla-Rosbertson J, Rivera LMR, Meneses-Garcia A: Odontogenic tumors in Mexico. A collaborative retrospective study of 349 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997, 84(6):672-675.
7. Yong Lu, Ming Xuan, Takashi Takata, Changmei Wang, Zhiou He, Zhiyu Zhou, et al: Odontogenic tumors. A demographic study of 759 cases in a Chinese population. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998, 86(6):707-714.
8. Singh P, Cook J: Tumours of the jaw. East Afr Med J 1956, 33(10):383-390.
9. Dodge OG: Tumors of the jaw, odontogenic tissues and maxillary antrum excluding Burkitt's lymphoma in Uganda Africans. Cancer 1965, 18:205-215.
10. Salvin G, Cameron HM: Ameloblastoma in Africans from Tanzania and Uganda. Brit J Cancer 1969, 28:31-38.
11. Simon EN, Merlux MA, Vahahula E, Ngassapa D, Stoelinga PJ: A 4-year prospective study on epidemiology and clinicopathological presentation of odontogenic tumors in Tanzania. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005, 99(5):598-602.
12. Wakiaga JM, Onyango JF, Awange DO: Clinico-pathological analysis of jaw tumours and tumour-like conditions at the Kenyanta National Hospital. East Afr Med J 1997, 74(2):65-68.
13. Krutchkoff DJ, Chen J, Eisenberg E, Katz RV: Oral cancer. A survey of 356 cases from the university of Connecticut oral pathology biopsy Service, 1975–1986. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1990, 70:192-8.
14. Ogunbodeo EO, Ugboke VI, Ojo MA: Oral malignancies in Ile-Ife, Nigeria. East Afr Med J 1997, 74(1):33-36.
15. Mbulateye SM, Katabira ET, Wabinga H, Parkin DM, et al: Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDS-cancer registry match study. Int J Cancer 2006, 118(4):985-90.
16. Goedert JJ, Cote TR, Virgo P, Scoopa SM, Kingma HM, Jaffe ES, Biggar RJ: Spectrum of AIDS-associated malignant disorders. Lancet 1998, 351(9119):1833-9.
17. Ziegler JL, Katongole-Mbidde E: Kaposis sarcoma in childhood: an analysis of 100 cases from Uganda and relationship to HIV infection. Int J Cancer 1996, 65(2):200-3.
18. Navazesh M: Current oral manifestation of HIV infection CDA. Journal 2001, 29(2):137-141.
19. Hodgson TA, Greenspan D, Greenspan JS: Oral lesions of HIV disease and HART in industrialized countries. Adv Dent Res 2006, 19:57-62.
20. Omar JM, Hamza, Matee MiN, Simon ENM, Kikwiwi E, Moshii PJ, Mugisu F, Milux FM, Verweij PE, Ven A JAM van der: Oral manifestations of HIV infection in children and adults receiving highly active anti-retroviral therapy [HAART] in Dar es Salaam, Tanzania. BMC Oral Health 2006, 6:12. doi: 10.1186/1472-6831-6-12.
21. The STD/AIDS Control Programme: HIV/AIDS surveillance report, 2000. Kampala, Ministry of Health; 2000.
22. UNAIDS: World Health Organization. Epidemiological fact sheets by country 2002. [http://www.who.int/epi/hiv-factsheets]. Accessed Feb 20, 2007
23. Al-Khateeb T, Al-Hadi Hamasha A, Almasri NM: Oral and maxillofacial tumours in North Jordanian children and adolescents: a retrospective analysis over 10 years. Int J Oral Maxillofac Surg 2003, 32:78-83.
24. Dargeon HW: Tumors of childhood-A clinical treatise. New York: Paul Hoeber, Inc; 1960.
25. O’Conor GT: Significant aspects of childhood lymphoma in Africa. Cancer Res 1963, 23:1514-1518.
26. Rollison DE, Engels EA, Halsey NA, Shah KV, Viscidi RP, Helzlsouer KJH: Lee Prediagnostic circulating antibodies to JC and BK human polyomaviruses and risk of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 2006, 15(3):543.
27. Buccheri G, Merrell PW, Carpenter WM: Relative frequency of central odontogenic tumors: A study of 1,088 cases from Northern California and comparison to studies from other parts of the world. J Oral Maxillofac Surg 2006, 64:1343-1352.
28. Buchner A, Merrell PW: Odontogenic cysts and tumors. In Peterson's principles of oral and maxillofacial surgery BC Decker Inc Hamilton. London; 2004.

Pre-publication history
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1472-6831/8/19/prepub